- Antibodies
- Cell Therapies
- Vaccines
- Others
Biologics Contract Manufacturing Market size was valued at USD 19,250.6 million in 2023 and is poised to grow at a 9.4% CAGR from 2024 to 2030. The COVID-19 epidemic in 2020 caused unparalleled growth. The main driving factors behind this expansion were the government's and major biopharmaceutical companies' increased investments aimed at boosting efficiency and productivity. Biologics outsourcing in biotechnology has emerged as a new trend. Orders and requests for biotech contract manufacturing are rising, mostly for coronavirus vaccines and treatments. More than forty queries concerning COVID-19-related projects have been received by Lonza. The supply chain is disrupted as a result of the COVID-19 epidemic.
Biologics Contract Manufacturing Market Key Developments:
- In June 2023, Cell and Gene Therapy Catapult and Albumedix have entered into a technology licensing agreement whereby Albumedix's most recent innovations will be used to enhance the production of viral vectors.
- In June 2023, Wuxi Biologics, which provides comprehensive solutions for the discovery, development, and production of biologics, has reported an increase in the amount of drug substances and drug products it can produce at its Wuppertal, Germany, site.
Biologics Contract Manufacturing Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Biologics Contract Manufacturing Market Dynamics
Continuous advances in biotechnology and biomedical science approaches have significantly improved the process of developing biologics for the treatment of a variety of chronic diseases. Recent advances in biologics are targeted at improving cell line development, protein identification, expression, and engineering. Several new technologies for producing self-adjuvating antigen-adjuvant fusion protein subunit vaccines have emerged in recent years. The availability of described platforms of new adjuvants has been shown to benefit in the development of novel vaccines. Furthermore, the usage of Nano systems has grown in recent years as a means of addressing delivery problems associated with the use of mRNA therapies in disease therapy. Nonetheless, supply chains have shown to be resilient, and worldwide supplies, manufacturing, and services related to biologics have not been significantly impacted. Several factors, including a strong pipeline of biologics, a rise in FDA NDA/BLA approvals, an increase in patent expirations, limited manufacturing capacity, and the need to realize cost savings, have led industry participants to choose contract manufacturing services for the development of biologics in order to remain competitive.
North-America Got Significant Share of
Biologics Contract Manufacturing Market Regional Analysis
Based on regions, the Market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is predicted to dominate the biologics contract manufacturing organizations market, due to the existence of two major economies, the United States and Canada. The United States has one of the world's largest pharmaceutical industries, accounting for a significant portion of market sales. The high prevalence of chronic diseases, the aging of the population, and the growing need for evidence-based practice have all contributed to the increasing demand for clinical trials in the US. In recent years, an increasing number of clinical trials have moved from academic medical facilities to community-based clinics to worldwide sites across multiple countries. Furthermore, CMOs have a strong presence in the region, adding to the market's expansion.
Latin America
Europe
Asia Pacific
Middle East
North America
Biologics Contract Manufacturing Market Segmentation
By product type
By Company Size
- Small
- Mid-sized
- Large
Frequently Asked Questions
The Biologics Contract Manufacturing Market was valued at USD 19,250.6 million in 2023 and is projected to reach USD 35,990.4 million by 2030, growing at a CAGR of 9.4%.
The rapid development of biologics has transformed the treatment of a wide range of therapeutic problems, contributing to the current exponential surge in demand for biological medicines.
The pharmaceutical industry appears to be embracing the era of biologics given the continuous advances in science and the growth of FDA-approved biologics.
Market research is segmented based on product type, company size and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1.Executive Summary |
| 2.Global Biologics Contract Manufacturing Market Introduction |
| 2.1.Global Biologics Contract Manufacturing Market - Taxonomy |
| 2.2.Global Biologics Contract Manufacturing Market - Definitions |
| 2.2.1.product type |
| 2.2.2.Company Size |
| 2.2.3.Region |
| 3.Global Biologics Contract Manufacturing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Biologics Contract Manufacturing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Biologics Contract Manufacturing Market By product type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Antibodies |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Cell Therapies |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vaccines |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Biologics Contract Manufacturing Market By Company Size , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Small |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Mid-sized |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Large |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Biologics Contract Manufacturing Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. product type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Antibodies |
| 8.1.2.Cell Therapies |
| 8.1.3.Vaccines |
| 8.1.4.Others |
| 8.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Small |
| 8.2.2.Mid-sized |
| 8.2.3.Large |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antibodies |
| 9.1.2.Cell Therapies |
| 9.1.3.Vaccines |
| 9.1.4.Others |
| 9.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Small |
| 9.2.2.Mid-sized |
| 9.2.3.Large |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antibodies |
| 10.1.2.Cell Therapies |
| 10.1.3.Vaccines |
| 10.1.4.Others |
| 10.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Small |
| 10.2.2.Mid-sized |
| 10.2.3.Large |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antibodies |
| 11.1.2.Cell Therapies |
| 11.1.3.Vaccines |
| 11.1.4.Others |
| 11.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Small |
| 11.2.2.Mid-sized |
| 11.2.3.Large |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antibodies |
| 12.1.2.Cell Therapies |
| 12.1.3.Vaccines |
| 12.1.4.Others |
| 12.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Small |
| 12.2.2.Mid-sized |
| 12.2.3.Large |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Wuxi Biologics |
| 13.2.2.Abzena Ltd. |
| 13.2.3.Fujifilm Inc. |
| 13.2.4.Boehringer Ingelheim GmbH |
| 13.2.5.Lonza |
| 13.2.6.Vetter |
| 13.2.7.Almac |
| 13.2.8.Catalent |
| 13.2.9.Reddy’s |
| 13.2.10.Thermo Fischer (Patheon) |
| 13.2.11.Farmar SA |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Wuxi Biologics
- Abzena Ltd.
- Fujifilm Inc.
- Boehringer Ingelheim GmbH
- Lonza
- Vetter
- Almac
- Catalent
- Reddy’s
- Thermo Fischer (Patheon)
- Farmar SA